相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cutaneous Melanoma Version 2.2019
Daniel G. Coit et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2019)
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2019)
1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
J S Weber et al.
ANNALS OF ONCOLOGY (2019)
Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma
Rohini Sharma et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Richard P. Tobin et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Systemic treatments for metastatic cutaneous melanoma
Sandro Pasquali et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)
Sanjiv S. Agarwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (US Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialaEuro
T. K. Eigentler et al.
ANNALS OF ONCOLOGY (2016)
Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy
Kelly M. McMasters et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
R. Dummer et al.
ANNALS OF ONCOLOGY (2015)
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
Peter Mohr et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma-An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
Lawrence E. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers
Jeroen P. Jansen et al.
BMC MEDICINE (2013)
Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Bin Lian et al.
CLINICAL CANCER RESEARCH (2013)
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study
Jean Jacques Grob et al.
EUROPEAN JOURNAL OF CANCER (2013)
Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Network meta-analysis of survival data with fractional polynomials
Jeroen P. Jansen
BMC MEDICAL RESEARCH METHODOLOGY (2011)
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Johan Hansson et al.
LANCET ONCOLOGY (2011)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Claus Garbe et al.
ONCOLOGIST (2011)
Network meta-analysis of parametric survival curves
Mario J. N. M. Ouwens et al.
RESEARCH SYNTHESIS METHODS (2010)
A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence
Kevin B. Kim et al.
MELANOMA RESEARCH (2009)
Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone:: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
C. Garbe et al.
ANNALS OF ONCOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha:: A controlled, randomised multicentre trial
Rudolf Stadler et al.
ACTA ONCOLOGICA (2006)
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
AMM Eggermont et al.
LANCET (2005)
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial:: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
UR Kleeberg et al.
EUROPEAN JOURNAL OF CANCER (2004)
Adjuvant interferon in high-risk melanoma: The AIM HIGH study-United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma
BW Hancock et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Adjuvant therapy of malignant melanoma
R Molife et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2002)
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
N Cascinelli et al.
LANCET (2001)
Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study
DA Cameron et al.
BRITISH JOURNAL OF CANCER (2001)
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
